Datapoint: FDA Approves Abecma for Multiple Myeloma
March 31
The FDA last week approved Bristol Myers Squibb’s and bluebird bio’s Abecma for the treatment of multiple myeloma in patients who have not responded to at least four previous rounds of treatment. Abecma is the first CAR-T cell therapy approved for multiple myeloma. This is the second CAR-T therapy for Bristol Myers, following Breyanzi’s lymphoma nod in February. Early data shows Breyanzi is currently covered for 9% of all insured lives, with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 3/29/21
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
